Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

(2014) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

(2014) Yang Zhang et al.   OncoTargets and Therapy

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer

(2013) C. Zielinski et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Targeting the MET gene for the treatment of non-small-cell lung cancer

(2013) F. Gelsomino et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

(2013) Kadoaki Ohashi et al.   JOURNAL OF CLINICAL ONCOLOGY

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell Lung Cancer

(2013) Young Tae Kim et al.   Journal of Thoracic Oncology

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Management of non-small-cell lung cancer: recent developments

(2013) Martin Reck et al.   LANCET

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

(2012) Hui Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients

(2012) Heae Surng Park et al.   LUNG CANCER

Tumor Immunotherapy Directed at PD-1

(2012) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual biological effects of the cytokines interleukin-10 and interferon-γ

(2011) Cailin Moira Wilke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

Overall survival and PD-L1 expression in metastasized malignant melanoma

(2010) Jules Gadiot et al.   CANCER

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

(2010) Yan Zhang et al.   Cellular & Molecular Immunology

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

(2010) Heounjeong Go et al.   Journal of Thoracic Oncology

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma

(2010) Mei-Chi Hsu et al.   MODERN PATHOLOGY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer

(2008) K. I. Al-Shibli et al.   CLINICAL CANCER RESEARCH

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA